VSTM Stock Overview
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Verastem, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$11.82 |
52 Week High | US$15.18 |
52 Week Low | US$4.20 |
Beta | 0.49 |
1 Month Change | -9.70% |
3 Month Change | 42.93% |
1 Year Change | 118.99% |
3 Year Change | -60.12% |
5 Year Change | -67.81% |
Change since IPO | -91.12% |
Recent News & Updates
Recent updates
Verastem: Moving Forward
Sep 13Health Check: How Prudently Does Verastem (NASDAQ:VSTM) Use Debt?
Sep 01Verastem Non-GAAP EPS of -$0.11 in-line
Aug 08Verastem: Looking Increasingly Attractive
Jun 29Verastem: Time To Take My Position Out Of Mothball
Apr 19Vectoring In On Verastem
Jan 12Verastem: Buying Opportunity Following Unjustified Sell-Off
Sep 22Does Verastem (NASDAQ:VSTM) Have A Healthy Balance Sheet?
Jun 23Verastem to highlight potential of ovarian cancer therapy on upcoming investor event
May 26Analysts Are Betting On Verastem, Inc. (NASDAQ:VSTM) With A Big Upgrade This Week
May 25Health Check: How Prudently Does Verastem (NASDAQ:VSTM) Use Debt?
Mar 02What Is The Ownership Structure Like For Verastem, Inc. (NASDAQ:VSTM)?
Feb 02Verastem Oncology: Targeting The RAS Pathway To Develop New Cancer Medicines
Jan 12Verastem Oncology appoints chief medical officer
Jan 06The Verastem (NASDAQ:VSTM) Share Price Is Up 68% And Shareholders Are Holding On
Jan 05Shareholder Returns
VSTM | US Biotechs | US Market | |
---|---|---|---|
7D | 0.3% | 0.9% | 0.4% |
1Y | 119.0% | 10.3% | 28.8% |
Return vs Industry: VSTM exceeded the US Biotechs industry which returned 9.6% over the past year.
Return vs Market: VSTM exceeded the US Market which returned 29.5% over the past year.
Price Volatility
VSTM volatility | |
---|---|
VSTM Average Weekly Movement | 9.9% |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: VSTM's share price has been volatile over the past 3 months.
Volatility Over Time: VSTM's weekly volatility has decreased from 20% to 10% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2010 | 73 | Dan Paterson | https://www.verastem.com |
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205.
Verastem, Inc. Fundamentals Summary
VSTM fundamental statistics | |
---|---|
Market cap | US$298.99m |
Earnings (TTM) | -US$87.37m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.4x
P/E RatioIs VSTM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
VSTM income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$87.37m |
Earnings | -US$87.37m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -3.45 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 56.4% |
How did VSTM perform over the long term?
See historical performance and comparison